subject area of
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Academic Article
- Biologic survival. Academic Article
- Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial Academic Article
- Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease Academic Article
- Clinical Decision Support Tool for Infliximab in Crohn’s Disease Academic Article
- Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease Academic Article
- Cytokine-Based Therapy in Psoriasis Academic Article
- Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study Academic Article
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Academic Article
- Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. Academic Article
- Immunotherapies in Dermatologic Disorders Academic Article
- Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab Academic Article
- Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis Academic Article
- Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study Academic Article
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study Academic Article
- The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies Academic Article
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease Academic Article
- Ustekinumab associated thrombotic thrombocytopenic purpura Academic Article
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Academic Article
- Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials Academic Article